Table 2.
Clinical characteristics and MRI parameters of 44 participants.
| Characteristic | Value |
|---|---|
| Age (y) | 60.0 ± 11.6 |
| Sex (men/women) | 39/5 |
| Size (cm2) | 38.4 ± 44.4 |
| ECOG (0/1) | 8/36 |
| Child–Pugh score (5/6) | 23/21 |
| HBsAg (+) | 29 (66) |
| Anti-HCV (+) | 8 (18) |
| Alcohol abuse † | 5 (11) |
| Cirrhosis †† | 34 (77) |
| Extrahepatic metastasis | 38 (86) |
| Macroscopic vascular invasion | 24 (55) |
| Serum AFP > 400 ng/mL | 29 (66) |
| Prior treatment | |
| Surgery | 20 (45) |
| Ablation | 8 (18) |
| TACE | 35 (80) |
| Sorafenib | 44 (100) |
Note: Unless otherwise indicated, data are mean ± standard deviation, and data in parentheses are percentages. AFP = alpha-fetoprotein; TACE = transarterial chemoembolization; ECOG = Eastern Cooperative Oncology Group; HBsAg = hepatitis B surface antigen; Anti-HCV = antihepatitis C antibody. † Alcohol abuse was defined as history of more than 3 drinks a day, documentation of alcoholism or alcohol abuse in a physician’s progress notes, or a history of alcoholic hepatitis. †† Cirrhosis was graded histologically (n = 4) or clinically (combined laboratory data and imaging, n = 30).